Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMRN

Amarin Corp ADR

Nov 05 • 04:00PM ET

15.31

+0.11 0.72 %

Healthcare • Drug Manufacturers - General • Ireland • NASD

Peers: GILD REGN VRTX NBIX SRPT MDGL DVAX VKTX AKBA ITCI

| Held by: SPDW GWX IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.17	Insider Own	0.42%	Shs Outstand	20.80M	Perf Week	-8.92%
Market Cap	318.45M	Forward P/E	107.00	EPS next Y	0.14	Insider Trans	0.00%	Shs Float	20.71M	Perf Month	-20.55%
Enterprise Value	38.29M	PEG	-	EPS next Q	0.03	Inst Own	17.18%	Short Float	1.65%	Perf Quarter	1.39%
Income	-85.92M	P/S	1.40	EPS this Y	83.46%	Inst Trans	0.53%	Short Ratio	3.49	Perf Half Y	50.39%
Sales	226.88M	P/B	0.69	EPS next Y	121.63%	ROA	-12.18%	Short Interest	0.34M	Perf YTD	57.84%
Book/sh	22.06	P/C	1.11	EPS next 5Y	76.88%	ROE	-17.35%	52W High	20.90 -26.75%	Perf Year	30.59%
Cash/sh	13.79	P/FCF	-	EPS past 3/5Y	- -24.69%	ROIC	-18.45%	52W Low	7.08 116.24%	Perf 3Y	-37.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-26.80% -11.92%	Gross Margin	37.78%	Volatility	5.25% 5.49%	Perf 5Y	-84.44%
Dividend TTM	-	EV/Sales	0.17	EPS Y/Y TTM	-115.62%	Oper. Margin	-28.07%	ATR (14)	0.97	Perf 10Y	-57.94%
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	-6.31%	Profit Margin	-37.87%	RSI (14)	30.69	Recom	4.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.45	EPS Q/Q	70.03%	SMA20	-16.86%	Beta	0.72	Target Price	11.33
Payout	-	Debt/Eq	0.01	Sales Q/Q	15.54%	SMA50	-9.38%	Rel Volume	0.83	Prev Close	15.20
Employees	275	LT Debt/Eq	0.01	Earnings	Oct 29 BMO	SMA200	14.48%	Avg Volume	98.09K	Price	15.31
IPO	Apr 01, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	95.35% 15.25%	Trades		Volume	81,264	Change	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7

Show Previous Ratings

Nov-03-25 08:30AM	Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 03:34PM	Amarin Corp PLC (AMRN) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 07:29AM	Amarin: Q3 Earnings Snapshot (Associated Press Finance) -11.25%
07:00AM	Amarin Reports Third Quarter 2025 Financial Results (GlobeNewswire)
09:57AM	Loading…
Oct-28-25 09:57AM	Earnings To Watch: Amarin Corp PLC (AMRN) Reports Q3 2025 Results (GuruFocus.com)
Oct-27-25 08:00AM	Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit (GlobeNewswire)
Oct-23-25 10:06AM	Do Options Traders Know Something About Amarin Stock We Don't? (Zacks)
Oct-20-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-15-25 08:00AM	Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT and EPA Mechanistic Data at the Canadian Cardiovascular Congress (GlobeNewswire)
Oct-06-25 09:41AM	Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Sep-26-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Sep-03-25 11:30AM	Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-31-25 08:30AM	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 (GlobeNewswire)
08:30AM	Loading…
Aug-30-25 08:30AM	New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups (GlobeNewswire)
Aug-25-25 08:00AM	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 (GlobeNewswire)
Aug-22-25 09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-06-25 09:40AM	Is Amarin (AMRN) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-31-25 10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
Jul-30-25 07:05AM	Amarin: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-29-25 05:19PM	Recordati 1H Net Rev Climbs 12% to 1.3 Bln on Rare Diseases Unit Strength (Exec Edge)
12:13PM	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9% (GlobeNewswire)
10:00AM	What To Expect From Amarin Corp PLC (AMRN) Q2 2025 Earnings (GuruFocus.com)
Jul-24-25 12:10PM	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
10:45AM	VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales (Zacks)
07:30AM	Loading…
Jul-23-25 07:30AM	Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 (GlobeNewswire)
Jul-21-25 09:40AM	Are Medical Stocks Lagging DexCom (DXCM) This Year? (Zacks)
Jul-18-25 09:25AM	Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin (Zacks)
Jul-17-25 03:00PM	3 Strong Buy Breakout Stocks for Explosive Returns (Zacks)
Jul-14-25 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-11-25 12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks)
Jul-02-25 09:40AM	Are Medical Stocks Lagging Amarin (AMRN) This Year? (Zacks)
Jul-01-25 09:17AM	Moderna Stock Gains on Encouraging Flu Vaccine Data (Zacks)
Jun-27-25 10:00AM	Best Momentum Stock to Buy for June 27th (Zacks)
Jun-25-25 11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
09:28AM	Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 07:05AM	RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE (GlobeNewswire) +27.26%
07:00AM	Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA (Icosapent Ethyl) in Europe (GlobeNewswire)
Jun-23-25 12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
Jun-20-25 09:46AM	Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid (Zacks) -5.93%
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-16-25 09:55AM	Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-10-25 12:00PM	Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
10:00AM	Best Momentum Stocks to Buy for June 10th (Zacks)
09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks)
06:50AM	New Strong Buy Stocks for June 10th (Zacks)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +7.34%
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks)
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 11:58AM	Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks)
11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks)
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
09:40AM	Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? (Zacks)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-23-25 10:01AM	Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases (Zacks)
09:57AM	EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort (Zacks)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks)
May-20-25 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
May-08-25 12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks) +5.21%
03:07AM	Amarin Corp PLC (AMRN) Q1 2025 Earnings Call Highlights: Strategic Global Expansion Amidst ... (GuruFocus.com)
May-07-25 11:01AM	Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:32AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-03-25 03:02AM	Standex International Corp (SXI) Q3 2025 Earnings Call Highlights: Record Margins and Strategic ... (GuruFocus.com)
Apr-29-25 04:15PM	Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-28-25 04:15PM	Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (GlobeNewswire)
Apr-09-25 07:30AM	Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change (GlobeNewswire) +6.63%
Apr-07-25 07:30AM	Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors (GlobeNewswire)
Mar-31-25 08:00AM	Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist (GlobeNewswire)
Mar-19-25 12:45PM	Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance (Business Wire) +6.31%
07:30AM	New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-13-25 03:02AM	Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... (GuruFocus.com)
Mar-12-25 12:45PM	Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript (Motley Fool) -14.94%
07:20AM	Amarin: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program (GlobeNewswire)
07:00AM	Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action (GlobeNewswire)

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRN

Amarin Corp ADR

Upgrade your FINVIZ experience